A new study is raising fresh questions about the efficacy of Gilead Sciences Inc’s anti-viral medication remdesivir in COVID-19 patients.
A randomized, controlled trial of remdesivir in 584 moderately ill COVID-19 patients hospitalized with pneumonia yielded disappointing results in research published on Friday in JAMA. Compared to standard care without remdesivir, a 10-day course of the drug did not show a statistically significant effect on disease course at 11 days after treatment started, the study found.
A five-day remdesivir course did make a statistically significant difference, but one so small that the researchers are not sure it really matters.
